- Sarepta's eteplirsen could be worth $1b, but Prosensa may reach market first
- Fragrance or foolery: 15 big drug events will resolve before April
- STOCKWATCH: Orphan and generic drugs diverge
- DEALS ROUND-UP: M&A and partnering 1-28 December
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.